title: Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.
abstract: In the past, patients with hemophilia and inhibitors have had less-than-optimal treatment and have experienced more orthopedic complications than patients without inhibitors. Bypassing agents offer the potential to close treatment gaps between inhibitor and noninhibitor patients by helping the former better attain key treatment goals, including: facilitating early initiation of treatment and hemostatic control in hemarthroses; providing effective treatment in serious hemorrhagic episodes; and performance of major surgery. Effective treatment with a bypassing agent minimizes joint and/or muscle damage and potentially can serve as an effective prophylactic agent to minimize the number of hemarthroses experienced per year, thereby mitigating the development of arthropathy. The reported efficacy of the currently available bypassing agents ranges from approximately 50-80% (50-64% in controlled studies) for plasma-derived activated prothrombin complex concentrate (pd-aPCC) and 81-91% (in controlled studies) for recombinant activated factor VII (rFVIIa), including use in major orthopedic surgery. Both bypassing agents have undergone key improvements in their formulation and/or properties in recent years. The nanofiltered, vapor-heated formulation of pd-aPCC has diminished the risk of acquiring blood-borne viral infections and the room temperature stable formulation of rFVIIa allows more convenient storage, increased ease to dissolve and inject, and smaller volumes, thereby increasing overall ease of administration. Use of recommended dosing has been demonstrated to provide effective hemostasis with a minimal number of injections for both agents. In this paper, we review the individual characteristics of pd-aPCC and rFVIIa and discuss clinical data from studies conducted in inhibitor patients that demonstrate the potential benefits of these bypassing agents in this difficult-to-treat population, and underscore the potential opportunities to close the gap in care between inhibitor and noninhibitor hemophilic patients.
authors.affiliation: Indiana Hemophilia and Thrombosis Center, 8402 Harcourt Road, Suite 500, Indianapolis, IN 46260, USA.
authors.forename: Amy D
authors.initials: AD
authors.lastname: Shapiro
authors.affiliation: University of Lund, Malmö, Sweden.
authors.forename: Ulla
authors.initials: U
authors.lastname: Hedner
keywords: hemophilia; inhibitors; outcomes; patient care; plasma-derived activated prothrombin complex concentrate; recombinant activated factor VII
references.citation: Annu Rev Med. 2008;59:29-41
references.pmid: 17845136
references.citation: J Intern Med. 1992 Jul;232(1):25-32
references.pmid: 1640190
references.citation: Semin Hematol. 2004 Jan;41(1 Suppl 1):51-4
references.pmid: 14872422
references.citation: Haemophilia. 2008 Mar;14(2):287-94
references.pmid: 18081834
references.citation: Scand J Haematol. 1976 May;16(5):369-82
references.pmid: 951577
references.citation: Transfus Sci. 1998 Jun;19(2):163-76
references.pmid: 10187041
references.citation: Thromb Res. 2010 Apr;125 Suppl 1:S16-8
references.pmid: 20188401
references.citation: Blood. 1983 Nov;62(5):1135-8
references.pmid: 6414555
references.citation: Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1381-9
references.pmid: 12231555
references.citation: Blood Coagul Fibrinolysis. 2008 Jun;19(4):276-82
references.pmid: 18469548
references.citation: Haemophilia. 2004 Jul;10(4):352-9
references.pmid: 15230949
references.citation: Haemophilia. 2002 Mar;8(2):83-90
references.pmid: 11952842
references.citation: Haemophilia. 2008 May;14(3):466-75
references.pmid: 18282155
references.citation: N Engl J Med. 2007 Aug 9;357(6):535-44
references.pmid: 17687129
references.citation: Haemophilia. 2004 Sep;10 Suppl 2:41-5
references.pmid: 15385045
references.citation: Acta Med Scand Suppl. 1962;379:111-90
references.pmid: 14490113
references.citation: J Thromb Haemost. 2003 Mar;1(3):450-5
references.pmid: 12871449
references.citation: Thromb Haemost. 2006 Apr;95(4):600-5
references.pmid: 16601828
references.citation: Drug Des Devel Ther. 2010 Jul 21;4:107-16
references.pmid: 20689697
references.citation: Thromb Haemost. 1998 Nov;80(5):773-8
references.pmid: 9843170
references.citation: Ann Intern Med. 1973 Jan;78(1):91-5
references.pmid: 4682314
references.citation: Blood. 2004 Apr 1;103(7):2467-73
references.pmid: 14615381
references.citation: Haemophilia. 1999 Mar;5(2):101-5
references.pmid: 10215957
references.citation: Haemophilia. 2007 Sep;13(5):606-12
references.pmid: 17880451
references.citation: J Thromb Haemost. 2007 Jul;5 Suppl 1:143-50
references.pmid: 17635720
references.citation: Semin Thromb Hemost. 2010 Jul;36(5):485-92
references.pmid: 20632246
references.citation: J Thromb Haemost. 2004 Oct;2(10):1700-8
references.pmid: 15456478
references.citation: Blood Coagul Fibrinolysis. 2005 Jun;16(4):259-66
references.pmid: 15870545
references.citation: Haemophilia. 2009 May;15(3):752-9
references.pmid: 19432926
references.citation: Blood. 1971 Apr;37(4):381-7
references.pmid: 5549716
references.citation: J Thromb Haemost. 2003 Nov;1(11):2374-80
references.pmid: 14629472
references.citation: Thromb Haemost. 2010 Feb;103(2):351-9
references.pmid: 20024491
references.citation: Haemophilia. 2001 Sep;7(5):517-22
references.pmid: 11554944
references.citation: Haemophilia. 2004 Sep;10 Suppl 2:50-2
references.pmid: 15385047
references.citation: Blood. 1981 Jul;58(1):38-44
references.pmid: 7236891
references.citation: Br J Clin Pharmacol. 2008 Jan;65(1):3-11
references.pmid: 17961193
references.citation: Br J Haematol. 1997 Dec;99(3):542-7
references.pmid: 9401063
references.citation: Blood Coagul Fibrinolysis. 1990 Jun;1(2):145-51
references.pmid: 2130926
references.citation: Haemophilia. 2010 Mar;16(2):263-71
references.pmid: 20028421
references.citation: Vasc Health Risk Manag. 2007;3(4):527-31
references.pmid: 17969383
references.citation: Acta Med Scand. 1983;214(3):191-7
references.pmid: 6660025
references.citation: Clin Adv Hematol Oncol. 2003 Feb;1(2):112-9
references.pmid: 16224390
references.citation: JAMA. 2006 Jan 18;295(3):293-8
references.pmid: 16418464
references.citation: Haemophilia. 1998 Nov;4(6):790-8
references.pmid: 10028299
references.citation: Crit Care. 2006;10(4):R104
references.pmid: 16859505
references.citation: Haemophilia. 2008 Sep;14(5):898-902
references.pmid: 18684126
references.citation: Haemophilia. 2010 Nov;16(6):902-9
references.pmid: 20518817
references.citation: Haemophilia. 2007 Sep;13(5):527-32
references.pmid: 17880439
references.citation: Thromb Res. 1996 Mar 1;81(5):533-43
references.pmid: 8907312
references.citation: J Thromb Haemost. 2007 Sep;5(9):1904-13
references.pmid: 17723130
references.citation: J Thromb Haemost. 2006 Dec;4(12):2576-81
references.pmid: 17002659
references.citation: Haemophilia. 2006 Dec;12 Suppl 6:48-52; discussion 52-3
references.pmid: 17123394
references.citation: J Thromb Haemost. 2006 Feb;4(2):367-71
references.pmid: 16420567
references.citation: Blood. 1979 Dec;54(6):1358-68
references.pmid: 508942
references.citation: J Bone Joint Surg Am. 1965 Mar;47:323-32
references.pmid: 14261808
references.citation: Blood Coagul Fibrinolysis. 1998 Mar;9(2):119-28
references.pmid: 9622209
references.citation: N Engl J Med. 1981 Sep 24;305(13):717-21
references.pmid: 6790990
references.citation: Haemophilia. 2004 Mar;10(2):174-8
references.pmid: 14962207
references.citation: Haemophilia. 2004 Sep;10 Suppl 2:3-9
references.pmid: 15385040
references.citation: Haemophilia. 2007 Sep;13(5):502-7
references.pmid: 17880436
references.citation: Haemophilia. 2004 Sep;10 Suppl 2:10-6
references.pmid: 15385041
references.citation: Haemophilia. 2008 Mar;14(2):233-41
references.pmid: 18081827
references.citation: Thromb Haemost. 1997 Jun;77(6):1113-9
references.pmid: 9241742
references.citation: Eur J Haematol Suppl. 1998;63:7-10
references.pmid: 9882925
references.citation: Clin Pharmacol Ther. 1994 Jun;55(6):638-48
references.pmid: 8004880
references.citation: N Engl J Med. 1980 Aug 21;303(8):421-5
references.pmid: 6771653
references.citation: Pharmacoeconomics. 2007;25(12):1007-29
references.pmid: 18047387
references.citation: Haemophilia. 2003 May;9(3):261-8
references.pmid: 12694515
references.citation: Thromb Haemost. 1998 Dec;80(6):912-8
references.pmid: 9869160
references.citation: Br J Haematol. 2003 Mar;120(5):808-13
references.pmid: 12614214
references.citation: Haemostasis. 1996;26 Suppl 1:118-23
references.pmid: 8904185
references.citation: Proc Natl Acad Sci U S A. 1989 Feb;86(4):1382-6
references.pmid: 2784006